Role of bradykinin in protection of ischemic preconditioning in rabbit hearts

Circulation Research

Volumn 77, Issue 3, 1995, Pages 611-621

  Goto, Mahiko ^a   Liu, Yongge ^a   Yang, Xi Ming ^a   Ardell, Jeffrey L ^a   Cohen, Michael V ^a   Downey, James M ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

adenosine; bradykinin; HOE 140; ischemic preconditioning; protein kinase C

Indexed keywords

BRADYKININ; BRADYKININ RECEPTOR; ICATIBANT; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; POLYMYXIN B; PROTEIN KINASE C INHIBITOR; STAUROSPORINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEMODYNAMICS; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

EID: 0029130667     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.77.3.611     Document Type: Article

References (71)

1. Dorheim TA, Wang T, Mentzer RM Jr, Van Wylen DGL. Inter-stitial purine metabolites during regional myocardial ischemia. J Surg Res. 1990;48:491-497.
2. Schömig A. Catecholamines in myocardial ischemia: systemic and cardiac release. Circulation. 1990;82(suppl II):II-13-II-22.
3. Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K. Role of locally formed angiotensin 11 and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res. 1993;27:334-340.
4. Liu GS, Thornton J, Van Winkle DM, Stanley AWH, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A, adenosine receptors in rabbit heart. Circulation. 1991;84:350-356.
5. 1-selective adenosine analogues protects the heart against infarction. Circulation. 1992;85:659-665.
6. Thornton JD, Daly JF, Cohen MV, Yang X-M, Downey JM. Catecholamines can induce adenosine receptor-mediated protection of the myocardium but do not participate in ischemic preconditioning in the rabbit. Circ Res. 1993;73:649-655.
7. Kitakaze M, Hori M, Kamada T. Role of adenosine and its interaction with α adrenoceptor activity in ischaemic and reperfusion injury of the myocardium. Cardiovasc Res. 1993;27:18-27.
8. 1-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5′-nucleotidase activity, J Clin Invest. 1994;93:2197-2205.
9. 1-Adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C. Circ Res. 1994;75:576-585.
10. Thornton JD, Thornton CS, Downcy JM. Effect of adenosine receptor blockade: preventing protective preconditioning depends on time of initiation. Am J Physiol. 1993;265:H504-H508.
11. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinasc C activation. Am J Physiol. 1994;266: H1145-H1152.
12. Liu Y, Ytrehus K, Downey JM. Evidence that translocation of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium. J Mol Cell Cardiol. 1994;26:661-668.
13. Vegh A, Szekeres L, Parratt JR. Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetized dogs. Br J Pharmacol. 1991;104: 294-295.
14. Vegh A, Papp JG, Szekeres L, Parratt JR. Prevention by an inhibitor of the L-arginine-nitric oxide pathway of the antiarrhythmic effects of bradykinin in anaesthetized dogs. Br J Pharmacol. 1993; 110:18-19.
15. Parratt JR. Protection of the heart by ischaemic preconditioning: mechanisms and possibilities for pharmacological exploitation. Trends Pharmacol Sci. 1994;15:19-25.
16. Parratt J. Endogenous myocardial protective (antiarrhythmic) substances. Cardiovasc Res. 1993;27:693-702.
17. Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther. 1994;270;681-689.
18. Ardell JL, Yang X-M, Thornton JD, Swafford A, Cohen MV, Downey JM. Depletion of norepinephrine by chronic surgical sympathectomy does not block protection from ischemic preconditioning. Circulation. 1994;90(suppl I):I-108. Abstract.
19. Ytrehus K, Liu Y, Tsuchida A, Miura T, Liu GS, Yang X-M, Herbert D, Cohen MV, Downey JM. Rat and rabbit heart infarction: effects of anesthesia, perfusate, risk zone, and method of infarct sizing. Am J Physiol. 1994;267:H2383-H2390.
20. Tanaka M, Fujiwara H, Yamasaki K, Sasayama S. Superoxide dismutase and N-2-mercaptopropionyl glycine attenuate infarct size limitation effect of ischaemic preconditioning in the rabbit. Cardiovasc Res. 1994;28:980-986.
21. Matsuki T, Shoji T, Yoshida S, Kudoh Y, Motoe M, Inoue M, Nakata T, Hosoda S, Shimamoto K, Yellon D, Iimura O. Sympathetically induced myocardial ischaemia causes the heart to release plasma kinin. Cardiovasc Res. 1987;21:428-432.
22. Baumgarten CR, Linz W, Kunkel G. Schölkens BA, Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol. 1993;108:293-295.
23. Nolly H, Carbini LA, Scicli G, Carretero OA, Scicli AG. A local kallikrein-kinin system is present in rat hearts. Hypertension. 1994; 23:919-923.
24. Martorana PA, Kettenbach B, Briepohl G, Linz W, Schölkens BA. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol. 1990;182:395-396.
25. Linz W, Schölkens BA. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 1992;20(suppl 9):S83-S90.
26. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol. 1993;21: 996-1003.
27. Hartman JC, Hullinger TG, Wall TM, Shebuski RJ. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol. 1993;234:229-236.
28. Parratt JR. Cardioprotection by angiotensin converting enzyme inhibitors - the experimental evidence. Cardiovasc Res. 1994;28: 183-189.
29. Massoudy P, Becker BF, Gerlach E. Bradykinin accounts for improved postischemic function and decreased glutathione release of guinea pig heart treated with the angiotensin-converting enzyme inhibitor ramiprilat. J Cardiovasc Pharmacol. 1994;23:632-639.
30. Ehring T, Baumgart D, Krajcar M, Hümmelgen M, Kompa S, Heusch G. Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide. Circulation. 1994;90:1368-1385.
31. Patel VC, Yellon DM, Singh KJ, Neild GH, Woolfson RG. Inhibition of nitric oxide limits infarct size in the in situ rabbit heart. Biochem Biophys Res Commun. 1993;194:234-238.
32. Rees DD, Palmer RMJ, Schulz R, Hodson HF, Moncada S, Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol. 1990;101:745-752.
33. Flower R, Gryglewski R, Herbaczyńska-Cedro K, Vane JR. Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nature. 1972;238:104-106.
34. Okada T. Hypoxia-induced changes in prostanoids production and coronary flow in isolated rat heart. J MoL Cell Cardiol. 1991;23: 939-948.
35. Casncllie JE. Protein kinase inhibitors: probes for the functions of protein phosphorylation. Adv Pharmacol. 1991;22:167-205.
36. Harding EA, Jaggar JH, Squires PE, Dunne MJ. Polymyxin has multiple blocking actions on the ATP-sensitive potassium channels in insulin-secreting cells. Pflugers Arch. 1994;426:31-39.
37. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res. 1992;70:223-233.
38. Toombs CF, Moore TL, Shebuski RJ. Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with gliben-clamide. Cardiovasc Res. 1993;27:617-622.
39. ATP. channel antagonist to attenuate preconditioning in rabbit myocardium. Cardiovasc Res. 1994;28:1337-1341.
40. Cohen MV, Downey JM. Preconditioning during ischemia: basic mechanisms and potential clinical applications. Cardiol Rev. 1995; 3:137-149.
41. Thornton JD, Liu GS, Downey JM. Pretreatment with pertussis toxin blocks the protective effects of preconditioning: evidence for a G-protein mechanism. J Mol Cell Cardiol. 1993;25:311-320.
42. + channel in mediating the effects of acetylcholine to mimic preconditioning in dogs. Circ Res. 1993;73: 1193-1201.
43. Hendrikx M, Toshima Y, Mubagwa K, Flameng W. Muscarinic receptor stimulation by carbachol improves functional recovery in isolated, blood perfused rabbit heart. Cardiovasc Res. 1993;27: 980-989.
44. Przyklenk K, Kloner RA. Acetylcholine acts as a 'preconditioning-mimetic' in the canine model. J Am Coll Cardiol. 1994;23:396A. Abstract.
45. Liu Y, Tsuchida A, Cohen MV, Downey JM. Pretreatment with angiotcnsin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol. 1995;27: 883-892.
46. Murray MA, Heistad DD, Mayhan WG. Role of protein kinase C in bradykinin-induced increases in microvascular permeability. Circ Res. 1991;68:1340-1348.
47. 2 receptor type. Am J Physiol. 1994;267: F871-F878.
48. Donié F, Reiser G. Mass measurements of inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate in a neuronal cell line stimulated with bradykinin: inositolphosphate response shows desensitization. Biochem Biophys Res Commun. 1991;181: 997-1003.
49. Dixon BS, Sharma RV, Dickerson T, Fortune J. Bradykinin and angiotensin II: activation of protein kinase C in arterial smooth muscle. Am J Physiol. 1994;266:C1406-C1420.
50. 2+ oscillations in phosphatidylcholine breakdown. Biochem J. 1992;283:347-354.
51. Fu T, Okano Y, Hagiwara M, Hidaka H, Nozawa Y. Bradykinin-induced translocation of protein kinase C in neuroblastoma NCB-20 cell: dependence on 1,2-diacylglycerol content and free calcium. Biochem Biophys Res Commun. 1989;162:1279-1286.
52. Tippmer S, Quitterer U, Kolm V, Faussner A, Roscher A, Mosthaf L, Müller-Esterl W, Häring H. Bradykinin induces translocation of the protein kinase C isoforms α, ε, and ζ. Eur Biochem. 1994;225: 297-304.
53. Mitchell MB, Parker CG, Meng X, Brew EC, Ao L, Brown JM, Harken AH, Banerjee A. Protein kinase C mediates preconditioning in isolated rat heart. Circulation. 1993;88(suppl I):I-633. Abstract.
54. Speechly-Dick ME, Mocanu MM, Yellon DM. Protein kinase C: its role in ischemic preconditioning in the rat. Circ Res. 1994;75: 586-590.
55. Li Y, Kloner RA. Does protein kinase C play a role in ischemic preconditioning in the rat? J Mol Cell Cardiol. 1994;26:CLXXXV. Abstract.
56. Brew EC, Rehring TF, Banerjee A. Bradykinin receptors mediate preconditioning through protein kinase C. Circulation. 1994; 90(suppl I):I-207. Abstract.
57. Kitakaze M, Minamino T, Shinozaki Y, Sakamoto H, Mori H, Kurihara T, Hori M. Activation of protein kinase C and subsequent activation of ectosolic 5′-nucleotidase as a major cause for the infarct size-limiting effect of ischemic preconditioning. Circulation. 1994;90(suppl I):I-207. Abstract.
58. Cave AC, Apstein CS. Inhibition of protein kinase C abolishes preconditioning against contractile dysfunction in the isolated blood perfused rat heart. Circulation. 1994;90(suppl I):I-208. Abstract.
59. Przyklenk K, Kloner RA. The protein kinase C inhibitor H-7 fails to attenuate the cardioprotective effects of ischcmic preconditioning in the canine model. FASEB J. 1994;8:A118. Abstract.
60. Vogt A, Barancik M, Weihrauch D, Arras M, Podzuweit T, Schaper W. Activation of protein kinase C fails to protect ischemic porcine myocardium from infarction in vivo. J Mol Cell Cardiol. 1994;26: CXVIII. Abstract.
61. Koloeassides KG, Galinanes M. The specific protein kinase C inhibitor chelcrythrine fails to inhibit ischemic preconditioning in the rat heart. Circulation. 1994;90(suppl I):I-208. Abstract.
62. Tsuchida A, Miura T, Miki T, Sakamoto J, Iimura O. Role of α-adrenergic receptor and protein kinase C in infarct size limitation by ischemic preconditioning in rat heart. Circulation. 1994; 90(suppl I);I-647. Abstract.
63. Cohen MV, Liu Y, Downey JM. Activation of protein kinase C is critical to the protection of preconditioning. In: Parratt JR. Wainwright CL. eds. Myocardial Preconditioning. Austin, Tex: RG Landes Co; 1995. In press.
64. Cohen MV, Walsh RS, Goto M, Downey JM. Hypoxia preconditions rabbit myocardium via adenosine and catccholamine release. J Mol Cell Cardiol. In press.
65. Van Winkle DM, Thornton JD, Downey DM, Downey JM. The natural history of preconditioning: cardioprotection depends on duration of transient ischemia and time to subsequent ischemia. Coron Artery Dis. 1991;2:613-619.
66. Van Wylen DGL. Effect of ischemic preconditioning on interstitial purine metabolite and lactate accumulation during myocardial ischemia. Circulation. 1994;89:2283-2289.
67. Bradamante S, Piccinini F, Delu C, Janssen M, de Jong JW. NMR evaluation of changes in myocardial high energy metabolism produced by repeated short periods of ischemia. Biochim Biophys Acta. 1995;1243:1-8.
68. 1 MF-2 smooth muscle cells. Proc Natl Acad Sci USA. 1992;89:7330-7334.
69. 6-phenylisopropyladenosine on myocardial inositol phosphate content and force of contraction. Br J Pharmacol. 1990;101:829-834.
70. Armour JA, Yuan B, Butler CK. Cardiac responses elicited by peptides administered to canine intrinsic cardiac neurons. Peptides. 1990;11:753-761.
71. Huang MH, Wolf SG, Armour JA. Ventricular arrhythmias induced by chemically modified intrinsic cardiac neurones. Cardiovasc Res. 1994;28:636-642.